Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Senores PharmaceuticalsNSE:SENORES -3.33%19 EV-to-EBITDA is 28.32 as of Aug. 31, 2026, which is 22% above its 10-year median of 23.19. GuruFocus rates NSE:SENORES with a GF Score™ of 19/100. The stock has 7 warning signs investors should review. Among 730 Drug Manufacturers companies, Senores Pharmaceuticals ranks worse than 79.86% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Senores Pharmaceuticals's enterprise value is ₹66,392 Mil.
Senores Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ₹2,344 Mil. Therefore, Senores Pharmaceuticals's EV-to-EBITDA for today is 28.32.
The historical rank and industry rank for Senores Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
NSE:SENORES'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 14.65 Med: 23.19 Max: 30.04
Current: 28.32
During the past 5 years, the highest EV-to-EBITDA of Senores Pharmaceuticals was 30.04. The lowest was 14.65. And the median was 23.19.
NSE:SENORES's EV-to-EBITDA is ranked worse than 79.86% of 730
companies
in the Drug Manufacturers industry
Industry Median: 13.47
vs NSE:SENORES: 28.32
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Senores Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Senores Pharmaceuticals's share price for today is ₹1432.80.
Senores Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹28.390.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:SENORES vs LLY, JNJ, ABBV: EV-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, Senores Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Senores Pharmaceuticals EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Senores Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Senores Pharmaceuticals's EV-to-EBITDA falls into.
Senores Pharmaceuticals's current Enterprise Value is ₹66,392 Mil.
Senores Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹2,344 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Senores Pharmaceuticals (NSE:SENORES) has a EV-to-EBITDA of 28.32 as of Aug. 31, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Senores Pharmaceuticals. This is 22% above median its historical median of 23.19. Over the past decade, Senores Pharmaceuticals' EV-to-EBITDA has ranged from 14.65 to 30.04. According to the industry distribution chart, Senores Pharmaceuticals ranks #583 out of 730 companies in the Drug Manufacturers industry, placing it in the top 79.9%.
Is Senores Pharmaceuticals' EV-to-EBITDA too high?
Senores Pharmaceuticals' current EV-to-EBITDA of 28.32 is 22% above median its 10-year median of 23.19. Over the past 10 years, this metric has ranged from a low of 14.65 to a high of 30.04. The Drug Manufacturers industry median EV-to-EBITDA is 13.47. Senores Pharmaceuticals' value of 28.32 is 110.2% above this industry median. Based on the distribution chart, Senores Pharmaceuticals ranks #583 out of 730 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Senores Pharmaceuticals has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Senores Pharmaceuticals' EV-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Senores Pharmaceuticals ranks #583 out of 730 companies for EV-to-EBITDA. This places Senores Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBITDA is 13.47. Senores Pharmaceuticals' value of 28.32 is 110.2% above this benchmark. Historically, Senores Pharmaceuticals' own EV-to-EBITDA has ranged from 14.65 to 30.04 over the past decade. While the company's 10-year median is 23.19 vs. the industry median of 13.47, Senores Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.47, based on 730 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Senores Pharmaceuticals's current EV-to-EBITDA of 28.32 is 110.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Senores Pharmaceuticals. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Senores Pharmaceuticals's current EV-to-EBITDA is 28.32, which is 22% above median its own 10-year median of 23.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senores Pharmaceuticals stock overvalued right now?
Senores Pharmaceuticals (NSE:SENORES) has a current EV-to-EBITDA of 28.32. The current EV-to-EBITDA is 28.32, which is 22% above median its 10-year median of 23.19 and 110.2% above the Drug Manufacturers industry median of 13.47. Senores Pharmaceuticals' overall GF Score™ is 19/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Senores Pharmaceuticals (NSE:SENORES), the current EV-to-EBITDA is 28.32 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Senores Pharmaceuticals Ltd is a research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the Regulated Markets of the USA, Canada and United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Its strength lies in identifying, developing and manufacturing a diverse range of specialty, underpenetrated and complex pharmaceutical products establishing the company as a preferred partner to certain customers. Through data analytics, research, market assessment and experienced management, It strategically identifies commercially underpenetrated molecules to launch products in the Regulated and Emerging Markets.
19GF Score
Get the complete analysis for NSE:SENORES
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SENORES has been successfully added to your 
